Intragenic ERBB2 kinase mutations in tumours

Stephens, Philip, Hunter, Chris, Bignell, Graham, Edkins, Sarah, Davies, Helen, Teague, Jon, Stevens, Claire, O'Meara, Sarah +52 more·2004·Nature
DOI 10.1038/431525b

Cited by (802)

Items 301–400 of 802

  1. Resistance to ErbB2 Tyrosine Kinase Inhibitors in Breast Cancer Is Mediated by Calcium-Dependent Activation of RelA
    Wenle Xia, Sarah S. Bacus, Intisar Husain, Lei-Hua Liu, Sumin Zhao, Zuguo Liu, Martin Arthur Moseley, J. Will Thompson, Franklin L. Chen, Kevin M. Koch et al. · 2010 · Molecular Cancer Therapeutics
  2. Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients
    Simon R. Turner, Darren J. Buonocore, Patrice Desmeules, Natasha Rekhtman, Snjezana Doğan, Oscar Lin, Maria E. Arcila, David Randolph Jones, James Guoxian Huang · 2018 · Lung Cancer
  3. Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion
    Quincy Siu-Chung Chu · 2020 · Therapeutic Advances in Medical Oncology
  4. Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion
    Mitsutoshi Nakada, Daisuke Kita, Lei Teng, Ilya V. Pyko, Takuya Watanabe, Yutaka Hayashi, Jun‐ichiro Hamada · 2012 · Advances in experimental medicine and biology
  5. Clinical experience with gefitinib: An update
    Federico Cappuzzo, Giovanna Finocchiaro, Giulio Metro, Stefania Bartolini, Elisabetta Magrini, Alessandra Cancellieri, Rocco Trisolini, Luciano Castaldini, Giovanni Tallini, L CRINO · 2006 · Critical Reviews in Oncology/Hematology
  6. Mutational analysis of NOTCH1, 2, 3 and 4 genes in common solid cancers and acute leukemias
    Sung Hak Lee, Eun Goo Jeong, Nam Jin Yoo, Sug Hyung Lee · 2007 · Apmis
  7. Genomic Approaches to Lung Cancer
    Roman Kurt Thomas, Barbara A. Weir, Matthew M. Meyerson · 2006 · Clinical Cancer Research
  8. Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer
    Wei Jiang, Meiju Ji · 2019 · Seminars in Cancer Biology
  9. Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers
    Juliana Eng, Meier Hsu, Jamie E. Chaft, Mark G. Kris, Maria E. Arcila, Bob T. Li · 2016 · Lung Cancer
  10. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis
    H Yokoyama, Yuzuru Ikehara, Yasuhiro Kodera, Sanae Kabata Ikehara, Yasushi Yatabe, Yoshinari Mochizuki, Masahiko Koike, Michitaka Fujiwara, Akimasa Nakao, Masae Tatematsu et al. · 2006 · British Journal of Cancer
  11. A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
    Tanios Bekaii‐Saab, Nita Williams, Christoph Plass, Miguel Villalona Calero, Charis Eng · 2006 · BMC Cancer
  12. Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
    Jorn Nützinger, Jii Bum Lee, Jia Li Low, Puey Ling Chia, Silvana Talisa Wijaya, Byoung Chul Cho, Sun Min Lim, Ross Andrew Soo · 2023 · Lung Cancer
  13. Molecular Mechanisms of Cardiotoxicity Induced by ErbB Receptor Inhibitor Cancer Therapeutics
    Anne-Sophie Hervent, G. De Keulenaer · 2012 · International Journal of Molecular Sciences
  14. Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer
    Jackie L. Johnson, Smitha Pillai, Srikumar Chellappan · 2012 · Biochemistry Research International
  15. The Molecular Genetics of Lung Cancer
    David S. Shames, Mitsuo Sato, John Dorrance Minna · 2008 · Lung Cancer
  16. ERBB oncogene proteins as targets for monoclonal antibodies
    Oleg L. Polanovsky, Ekaterina N. Lebedenko, Sergey Mikhailovich Deyev · 2012 · Biochemistry (Moscow)
  17. Aberrant Receptor Signaling and Trafficking as Mechanisms in Oncogenesis
    Tor Erik Rusten, Kaisa Haglund, Harald Stenmark · 2007 · Critical Reviews™ in Oncogenesis
  18. Genomics and the second golden era of cancer drug development
    Paul Workman · 2005 · Molecular BioSystems
  19. Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Luca Toschi, Federico Cappuzzo · 2007 · The Oncologist
  20. HER2 in Solid Tumors: More than 10 Years Under the Microscope; where are we now?
    Vittoria Martin, Federico Cappuzzo, Luca Mazzucchelli, Milo Frattini · 2014 · Future Oncology
  21. ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis
    Changliang Chen, Prachi Gupta, Deepak Parashar, Gopa Kumar Gopinadhan Nair, Jasmine George, Anjali Geethadevi, Wei Wang, Shirng‐Wern Tsaih, William Hampton Bradley, Ramani Ramchandran et al. · 2020 · Oncogene
  22. Atomistic Insights into Regulatory Mechanisms of the HER2 Tyrosine Kinase Domain: A Molecular Dynamics Study
    Shannon Telesco, Ravi Radhakrishnan · 2009 · Biophysical Journal
  23. Mutational Activation of ErbB2 Reveals a New Protein Kinase Autoinhibition Mechanism
    Ying‐Xin Fan, Lily Wong, Jinhui Ding, Nikolay A. Spiridonov, Richard C. Johnson, Gibbes R. Johnson · 2007 · Journal of Biological Chemistry
  24. Successful Targeting of the Warburg Effect in Prostate Cancer by Glucose-Conjugated 1,4-Naphthoquinones
    Sergey A. Dyshlovoy, Dmitry N. Pelageev, Jessica Hauschild, Ksenia L. Borisova, Moritz Kaune, Christoph Krisp, Simone Venz, Yu. E. Sabutskii, Ekaterina A. Khmelevskaya, Tobias Busenbender et al. · 2019 · Cancers
  25. The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-βSignaling in Breast Cancer Malignancy
    Shizhen Emily Wang · 2011 · Journal of Signal Transduction
  26. ERBB2 kinase domain mutation in the lung squamous cell carcinoma
    Jong Woo Lee, Young Hwa Soung, Su Young Kim, Suk Woo Nam, Won Sang Park, Young Pil Wang, Keon Hyun Jo, Seok Whan Moon, Sang Yong Song, Jung Young Lee et al. · 2005 · Cancer Letters
  27. Mutational analysis of gene families in human cancer
    Alberto Bardelli, Victor E. Velculescu · 2004 · Current Opinion in Genetics & Development
  28. Targeting ADAMS and ERBBs in lung cancer
    Nancy E. Hynes, Thomas Schlange · 2006 · Cancer Cell
  29. Identification of the Coexisting HER2 Gene Amplification and Novel Mutations in the HER2 Protein-Overexpressed Mucinous Epithelial Ovarian Cancer
    Wea‐Lung Lin, Wu‐Hsien Kuo, Fong‐Lin Chen, Ming‐Yung Lee, Alexandra Ruan, Yeu‐Sheng Tyan, Jeng‐Dong Hsu, Hung Chiang, Chih‐Ping Han · 2011 · Annals of Surgical Oncology
  30. Targeted therapy for NSCLC with driver mutations
    Gabriele Minuti, Armida D’Incecco, Federico Cappuzzo · 2013 · Expert Opinion on Biological Therapy
  31. DNA Sequencing of Cancer: What Have We Learned?
    Juliann Chmielecki, Matthew M. Meyerson · 2013 · Annual Review of Medicine
  32. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators
    S E Wang, Yang Yu, Tracy L. Criswell, Laura M. DeBusk, Ping‐Chang Lin, Roy Zent, D H Johnson, Xiubao Ren, Carlos L. Arteaga · 2010 · Oncogene
  33. Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma
    Shingo Matsumoto, Reika Iwakawa, Takashi Kohno, Kenji Suzuki, Yoshihiro Matsuno, Seiichiro Yamamoto, Masayuki Noguchi, Eiji Shimizu, Jun Yokota · 2005 · International Journal of Cancer
  34. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma
    Fengrui Zhou, Xin Wang, Fang Liu, Qingwei Meng, Yan Yu · 2020 · International Journal of Clinical Oncology
  35. Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas
    Avaniyapuram Kannan Murugan, Ahmad Alzahrani · 2022 · British Journal of Biomedical Science
  36. Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2–Targeted Therapy
    Siraj Mahamed Ali, R. Katherine Alpaugh, Sean R. Downing, Philip J. Stephens, Jian Qin Yu, Hong Gyun Wu, Jamie K. Buell, Vincent A. Miller, Doron Lipson, Gary A. Palmer et al. · 2014 · Journal of Clinical Oncology
  37. Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition
    Weiguo Xu, Shiro Soga, Kristen L. Beebe, M-J Lee, Young Shin Kim, Jane B. Trepel, Len Neckers · 2007 · British Journal of Cancer
  38. Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer
    Takashi Kubo, Yukie Kuroda, Hiroko Shimizu, Akiko Kokubu, Naoko Okada, Fumie Hosoda, Yasuhito Arai, Yu Nakamura, Hirokazu Taniguchi, Kazuyoshi Yanagihara et al. · 2009 · Carcinogenesis
  39. Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease
    Yosef Yarden, Deric L. Wheeler · 2014 · Springer eBooks
  40. A Subset of Lung Adenocarcinomas and Atypical Adenomatous Hyperplasia–Associated Foci Are Genotypically Related
    Giuliana Sartori, Alberto Cavazza, Federica Bertolini, Lucia Longo, Alessandro Marchioni, Matteo Costantini, Fausto Barbieri, Mario Migaldi, Giulio Rossi · 2008 · American Journal of Clinical Pathology
  41. Genomic landscape of lung adenocarcinomas in different races
    Shi H, Karan Seegobin, Fei Heng, Kexun Zhou, Ruqin Chen, Hong Qin, Rami Manochakian, Yujie Zhao, Yanyan Lou · 2022 · Frontiers in Oncology
  42. The Potential Role of Aerobic Exercise to Modulate Cardiotoxicity of Molecularly Targeted Cancer Therapeutics
    Jessica M. Scott, Susan C. Gilchrist, John Robert Mackey, Pamela S. Douglas, Mark J. Haykowsky, Lee W. Jones · 2013 · The Oncologist
  43. Mutational Analyses of Multiple Oncogenic Pathways in Intraductal Papillary Mucinous Neoplasms of the Pancreas
    Frank Schönleben, John Allendorf, Wanglong Qiu, Xiaojun Li, Daniel J. Ho, Nancy T. Ciau, Robert Lance Fine, John A. Chabot, Helen Elaine Remotti, Gloria H. Su · 2008 · Pancreas
  44. Targeted Therapies in Lung Cancer
    Lucian R. Chirieac, Sanja Đačić · 2010 · Surgical pathology clinics
  45. Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma
    Junichi Soh, Shinichi Toyooka, Keitaro Matsuo, Hiromasa Yamamoto, Ignacio Ivan Wistuba, Stephen C. Lam, Kwun Meng Fong, Adi F. Gazdar, Shinichiro Miyoshi · 2015 · Oncology Letters
  46. EGFR forms ligand-independent oligomers that are distinct from the active state
    Patrick O. Byrne, Kalina A. Hristova, Daniel J. Leahy · 2020 · Journal of Biological Chemistry
  47. HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib
    Bob T. Li, Adrian Lee, Sandra A O'Toole, Wendy Cooper, Bing Yu, Jamie E. Chaft, Maria E. Arcila, Mark G. Kris, Nick Pavlakis · 2015 · Lung Cancer
  48. A growing family: Adding mutated Erbb4 as a novel cancer target
    Udo Rudloff, Yardena Samuels · 2010 · Cell Cycle
  49. A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)
    Kiichiro Ninomiya, Tae Hata, Hiroshige Yoshioka, Kadoaki Ohashi, Akihiro Bessho, Shinobu Hosokawa, Nobuhisa Ishikawa, Masahiro Yamasaki, Takuo Shibayama, Keisuke Aoe et al. · 2019 · CHEST Journal
  50. The genomic landscape of nonsmall cell lung carcinoma in never smokers
    Bram Boeckx, Rajendra Bahadur Shahi, Dominiek Smeets, Sylvia De Brakeleer, Lore Decoster, Thomas Van Brussel, D. Galdermans, Piet Vercauter, Lynn Decoster, Patrick Alexander et al. · 2019 · International Journal of Cancer
  51. MicroRNA and HER2-overexpressing Cancer
    Shizhen Wang, Ren-Jang Lin · 2013 · MicroRNA
  52. Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
    Guangyuan Li, Xiaoqi Wang, Hanina H. Hibshoosh, Cheng Jin, Balázs Halmos · 2014 · PLoS ONE
  53. Receptor-Targeted Cancer Therapy
    Mark Richter, Hongtao Zhang · 2005 · DNA and Cell Biology
  54. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going
    Rafael Rosell, Mauricio A. Cuello, Fabiana Letizia Cecere, Mariacarmela Santarpía, Noemı́ Reguart, Enriqueta Felip, Miquel Tarón · 2006 · Current Opinion in Oncology
  55. A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing
    Torstein Tengs, Jeff C. Lee, J. Guillermo Paez, Xiaojun Zhao, Thomas LaFramboise, Georgia Giannoukos, Roman Kurt Thomas · 2005 · Cancer Letters
  56. ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas
    Eun Goo Jeong, Young Hwa Soung, Jong Woo Lee, Sung Hak Lee, Suk Woo Nam, Jung Young Lee, Nam Jin Yoo, Sug Hyung Lee · 2006 · International Journal of Cancer
  57. Oncogenes Come of Age
    HAROLD E. VARMUS, William J. Pao, Katerina A. Politi, Katrina Podsypanina, Yi Du · 2005 · Cold Spring Harbor Symposia on Quantitative Biology
  58. EGF and TGF-1 Effects on Thyroid Function
    Gabriella Mincione, Maria Carmela Di Marcantonio, Chiara Tarantelli, Sonia D'inzeo, Arianna Nicolussi, Francesco Nardi, Caterina Francesca Donini, Anna Coppa · 2011 · Journal of Thyroid Research
  59. Structure-Functional Prediction and Analysis of Cancer Mutation Effects in Protein Kinases
    Anshuman Dixit, Gennady M. Verkhivker · 2014 · Computational and Mathematical Methods in Medicine
  60. NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease
    Anna Michelotti, Marco de Scordilli, Elisa Bertoli, Elisa De Carlo, Alessandro Del Conte, Alessandra Bearz · 2022 · International Journal of Molecular Sciences
  61. Lung Adenocarcinoma Harboring Mutations in the ERBB2 Kinase Domain
    Makoto Sonobe, Toshiaki Manabe, Hiromi Wada, Fumihiro Tanaka · 2006 · Journal of Molecular Diagnostics
  62. Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer
    Shi Bu, Rui Wang, Yunjian Pan, Su Jeong Yu, Xuxia Shen, Yuan Li, Yihua Sun, Haiquan Chen · 2016 · Annals of Surgical Oncology
  63. Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer
    Hisashi Nakamura, Shinzo Takamori, Teruhiko Fujii, Mayumi Ono, Hideaki Yamana, Michihiko Kuwano, Kazuo Shirouzu · 2005 · Cancer Letters
  64. Genomics of Squamous Cell Lung Cancer
    Melissa Rooney, Siddhartha H. K. Devarakonda, Ramaswamy Govindan · 2013 · The Oncologist
  65. The significance of gene mutations across eight major cancer types
    Prosenjit Paul, Arup Kumar Malakar, Supriyo Chakraborty · 2019 · Mutation Research/Reviews in Mutation Research
  66. Microsatellite and EGFR, HER2 and K-RAS Analyses in Sclerosing Hemangioma of the Lung
    Giuliana Sartori, Stefania Raffaella Bettelli, Laura Schirosi, Nazzarena Bigiani, Antonino Maiorana, Alberto Cavazza, Giulio Rossi · 2007 · The American Journal of Surgical Pathology
  67. HER‐2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine
    Serenella Maria Pupa, Elda Tagliabue, Sylvie Ménard, Andrea Anichini · 2005 · Journal of Cellular Physiology
  68. PARP inhibition induces BAX/BAK‐independent synthetic lethality of BRCA1‐deficient non‐small cell lung cancer
    Ian Paul, Kienan I. Savage, Jaine K. Blayney, Elisabeth Lamers, Kathy A. Gately, Keith M. Kerr, Michael T. Sheaff, Ken Arthur, Derek J. Richard, Peter W. Hamilton et al. · 2011 · The Journal of Pathology
  69. Splicing Regulation: A Molecular Device to Enhance Cancer Cell Adaptation
    Vittoria Pagliarini, Chiara Naro, Claudio Sette · 2015 · BioMed Research International
  70. Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
    Xiangyi Kong, Kai Zhang, Xiangyu Wang, Xue Cheng Yang, Yalun Li, Jie Zhai, Zeyu Xing, Yihang Qi, Ran Gao, Xiaoli Feng et al. · 2019 · Cancer Management and Research
  71. The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
    Martina Kirchner, Klaus Kluck, Regine Brandt, Anna‐Lena Volckmar, Roland Penzel, Daniel N. Kazdal, Volker Endris, Olaf Neumann, Huriye Seker‐Cin, Hannah Goldschmid et al. · 2021 · ESMO Open
  72. The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma
    Karen L. Talia, Natalie Banet, Natália Buza · 2022 · Pathology
  73. Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress
    Samuel Rosner, Augusto Valdivia, Hui Jing Hoe, Joseph Christopher Murray, Benjamin Philip Levy, Enriqueta Felip, Benjamin Solomon · 2023 · American Society of Clinical Oncology Educational Book
  74. EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates
    Daniel Sentana‐Lledo, Emmeline C. Academia, Hollis Viray, Deepa Rangachari, Susumu S. Kobayashi, Paul A. VanderLaan, Daniel Botelho Costa · 2023 · Translational Lung Cancer Research
  75. Point mutations of protein kinases and individualised cancer therapy
    Michael A. Davies, Bryan T. Hennessy, Gordon Brent Mills · 2006 · Expert Opinion on Pharmacotherapy
  76. EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung cancer
    Xiaofeng Lin, Shuangshuang Zhong, Xiaofeng Ye, Yueling Liao, Feng Yao, Xiaohua Yang, Beibei Sun, Jie Zhang, Qi Li, Yong Gao et al. · 2014 · Molecular Cancer
  77. Breaking boundaries: role of the brain barriers in metastatic process
    Nasim Izadi, Peter Solar, Klaudia Hašanová, Alemeh Zamani, Muhammad Bilal Akbar, Klára Mrázová, Martin Bartošík, Tomáš Kazda, Roman Hrstka, Marek Joukal · 2025 · Fluids and Barriers of the CNS
  78. Prioritization of candidate cancer genes—an aid to oncogenomic studies
    Simon J. Furney, Borja Calvo, Pedro Larrañaga, Jose Antonio Lozano, Núria López-Bigas · 2008 · Nucleic Acids Research
  79. Clinical and genetic features of lung squamous cell cancer in never-smokers
    Yangle Huang, Rui Wang, Yunjian Pan, Yang Zhang, Hang Li, Chao Cheng, Difan Zheng, Shanbo Zheng, Yuan Li, Xuxia Shen et al. · 2016 · Oncotarget
  80. Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion
    Mitsutoshi Nakada, Daisuke Kita, Lei Teng, Ilya V. Pyko, Takuya Watanabe, Yutaka Hayashi, Jun‐ichiro Hamada · 2020 · Advances in experimental medicine and biology
  81. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
    Yeon Hee Park, Hyun‐Tae Shin, Hae Hyun Jung, Yoon‐La Choi, TaeJin Ahn, Kyunghee Park, Aeri Lee, In‐Gu Do, Ji‐Yeon Kim, Jin Seok Ahn et al. · 2015 · Oncotarget
  82. Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients
    Zhefeng Liu, Lin Wu, Jun Cao, Zhe Yang, Chengzhi Zhou, Liming Cao, Hao Wu, Haibo Shen, Meiling Jin, Yong Zhang et al. · 2018 · OncoTargets and Therapy
  83. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro
    Habib Zarredar, Shadi Pashapour, Khalil Ansarin, Majid Khalili, Roghayyeh Baghban, Safar Farajnia · 2018 · Journal of Cellular Physiology
  84. Targetable “Driver” Mutations in Non Small Cell Lung Cancer
    R. Vijayalakshmi, Arvind Krishnamurthy · 2011 · Indian Journal of Surgical Oncology
  85. Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives
    Tobias Boch, Jens Köhler, Melanie Janning, Sonja Loges · 2022 · Cancer Biology and Medicine
  86. Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases
    Andrew Shih, Shannon Telesco, Sung-Hee Choi, Mark A. Lemmon, Ravi Radhakrishnan · 2011 · Biochemical Journal
  87. Recent developments related to the EGFR as a target for cancer chemotherapy
    Georgina Speake, B. R. Holloway, Gerard F. Costello · 2005 · Current Opinion in Pharmacology
  88. Absence of AKT1 Mutations in Glioblastoma
    Fonnet E. Bleeker, Simona Lamba, Carlo Zanon, Angela A. van Tilborg, Sieger Leenstra, Dirk Troost, Theo J.M. Hulsebos, William Peter Vandertop, Alberto Bardelli · 2009 · PLoS ONE
  89. Somatic Mutations in Human Cancer: Insights from Resequencing the Protein Kinase Gene Family
    P. Andrew Futreal, Richard Wooster, Michael R. Stratton · 2005 · Cold Spring Harbor Symposia on Quantitative Biology
  90. Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment
    Gerald Steven Falchook, Filip Jankú, Anne S. Tsao, Christel C. Bastida, David J. Stewart, Razelle Kurzrock · 2013 · Journal of Thoracic Oncology
  91. Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?
    Sai‐Hong Ignatius Ou · 2013 · Journal of Clinical Pathology
  92. Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer
    Arielle J. Medford, Taronish D. Dubash, Dejan Juric, Laura M. Spring, Andrzej Niemierko, Neelima Vidula, Jeffrey M. Peppercorn, Steven Jay Isakoff, Brittany A. Reeves, Joseph A. LiCausi et al. · 2019 · npj Precision Oncology
  93. Exploring mechanisms of skin aging: insights for clinical treatment
    Meiqi Zhang, Yumeng Lin, Zhongyu Han, Xuewen Huang, Shuwei Zhou, Siyu Wang, Yan Zhou, Xuan Han, Haoran Chen · 2024 · Frontiers in Immunology
  94. Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China
    Fei Xu, Guangjian Yang, Haiyan Xu, Lu Yang, Weini Qiu, Junling Li, Yan Wang · 2020 · Thoracic Cancer
  95. Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer
    Mo Shen, Rongbin Qi, Justin Ren, Dongqing Lv, Haihua Yang · 2022 · Frontiers in Oncology
  96. Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer
    Mukesh Kumar, Vinicius Ernani, Taofeek Kunle Owonikoko · 2015 · Molecular Aspects of Medicine
  97. Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway
    Tomoaki Ohtsuka, Masakiyo Sakaguchi, Hiromasa Yamamoto, Shuta Tomida, Katsuyoshi Takata, Kazuhiko Shien, Shinsuke Hashida, Tomoko Miyata‐Takata, Mototsugu Watanabe, Ken Suzawa et al. · 2016 · Scientific Reports
  98. Recent Advances in Personalized Lung Cancer Medicine
    Ross A. Okimoto, Trever Grant Bivona · 2014 · Personalized Medicine
  99. Targeting Receptor Tyrosine Kinases in Cancer
    Wolfgang J. Köstler, Christoph Carl Zielinski · 2014 · Springer eBooks
  100. Somatic pharmacogenomics in cancer
    Ogechi N. Ikediobi · 2008 · The Pharmacogenomics Journal